This company operates as an Anglo-Swedish multinational pharmaceutical and biopharmaceutical specialised in the discovery, development, manufacture, and commercialization of prescription medicines. It was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group. It has its headquarters in Cambridge, United Kingdom and research and development (R&D) headquarters in Sodertalje, Sweden and in Warsaw, Poland, and Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals.The company has a portfolio of products for major disease areas including oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. It serves primary care and specialty care physicians through distributors and local representative offices. The company's pipeline includes 132 projects, of which 120 are in the clinical phase of development. It has collaboration agreements with Valeant Holdings Ireland, and Eli Lilly and Company; definitive agreement with Foundation Medicine, Inc.; strategic collaboration with FibroGen, Astellas, and Pieris Pharmaceuticals Inc; collaboration and license agreement with Celgene International Sarl; and license agreement with LEO Pharma A/S.
The read only version of the questionnaire submitted to this company is publicly available: view questionnaire.